公开(公告)号：US20250017921A1

公开(公告)日：2025-01-16

申请号：US18043298

申请日：2021-09-07

Applicant: IDEAYA Biosciences Inc.

Inventor： Zineb Mounir ,  Marie-Claire Wagle ,  Nandini Ravindran ,  Divya Pankajakshan ,  Mark R. Lackner

IPC: A61K31/497 ,  A61K31/4545 ,  A61P35/04 ,  C12Q1/6886 ,  G01N33/574

Abstract: A combination therapy is described involving a selective protein kinase C inhibitor and a cMET inhibitor, which is useful for treating metastatic uveal melanoma and other proliferative diseases, such as a tumor having a GNAQ or GNA11 mutation. The combination therapy can be provided by a pharmaceutical product, a method of treatment, or a kit. The combination therapy can involve use of a protein kinase C inhibitor and a cMET inhibitor. Also provided are methods useful for selecting patients or directing a course of treatment. In various examples, the protein kinase C can have the structure according to Formula II.